We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Cooper Companies (COO) Increase Share Repurchase Program
Read MoreHide Full Article
The Cooper Companies, Inc. (COO - Free Report) recently announced that it has approved a $500.0 million increase in its ongoing share repurchase program. In Dec 2011, the company had first authorized a share repurchase program and subsequently amended the total repurchase authorization to $500.0 million.
Stock Performance
A glimpse of the company’s price trend reveals that the stock has had a strong run on the bourse year to date. Cooper Companies added 11.65% versus the Zacks classified Medical/Dental-Supplies sub-industry’s gain of 8.50%.
Despite the bullish price trend, estimate revision for the stock has been unfavourable. In fact, the ongoing quarter saw seven analysts move south over the last seven days and two moving in the opposite direction. As a result, the Zacks Consensus Estimate for the ongoing quarter fell by two cents to $2.25, over the same time frame. Presently, the stock has a Zacks Rank #3 (Hold).
Coming back to the news, with the $500 million increase the share repurchase program now totals to $1 billion. Of this approximately $618.5 million is remaining with no expiration date. As of Jan 31, 2017, the company had $91.1 million in cash and $902.8 million available under its syndicated revolving credit agreement.
Going forward, the company is expected to maintain growth through leading positions in markets of speciality lenses with highly exclusive products like Bioinfinity, Clarity and silicone hydrogel lenses. The company's growing presence in the women's healthcare market through accretive acquisitions is also a positive in our view. However, of the major concerns, an unfavorable foreign exchange rate, intensifying competition and volatility at distributor base might dent growth.
Taking the stable performance of the stock into consideration, we expect The Cooper Companies to scale higher in the coming quarters. In this regard, a positive long-term growth of 11.8% holds promise.
Based in Pleasanton, CA, The Cooper Companies is a specialty medical device company operating on a global basis. It operates through two business segments, namely CooperVision and CooperSurgical.
Inogen has a long-term expected earnings growth rate of 17.05%. Notably, the stock has an impressive one-year return of 77.4%.
Avinger projects sales growth of 30.6% for the current year. Additionally, the company delivered a positive earnings surprise of 27% last quarter.
Fluidigm Corporation has a long-term expected earnings growth rate of 25%. The stock added 6.08%, in the last one year.
5 Trades Could Profit ""Big-League"" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Cooper Companies (COO) Increase Share Repurchase Program
The Cooper Companies, Inc. (COO - Free Report) recently announced that it has approved a $500.0 million increase in its ongoing share repurchase program. In Dec 2011, the company had first authorized a share repurchase program and subsequently amended the total repurchase authorization to $500.0 million.
Stock Performance
A glimpse of the company’s price trend reveals that the stock has had a strong run on the bourse year to date. Cooper Companies added 11.65% versus the Zacks classified Medical/Dental-Supplies sub-industry’s gain of 8.50%.
Despite the bullish price trend, estimate revision for the stock has been unfavourable. In fact, the ongoing quarter saw seven analysts move south over the last seven days and two moving in the opposite direction. As a result, the Zacks Consensus Estimate for the ongoing quarter fell by two cents to $2.25, over the same time frame. Presently, the stock has a Zacks Rank #3 (Hold).
Coming back to the news, with the $500 million increase the share repurchase program now totals to $1 billion. Of this approximately $618.5 million is remaining with no expiration date. As of Jan 31, 2017, the company had $91.1 million in cash and $902.8 million available under its syndicated revolving credit agreement.
Going forward, the company is expected to maintain growth through leading positions in markets of speciality lenses with highly exclusive products like Bioinfinity, Clarity and silicone hydrogel lenses. The company's growing presence in the women's healthcare market through accretive acquisitions is also a positive in our view. However, of the major concerns, an unfavorable foreign exchange rate, intensifying competition and volatility at distributor base might dent growth.
Taking the stable performance of the stock into consideration, we expect The Cooper Companies to scale higher in the coming quarters. In this regard, a positive long-term growth of 11.8% holds promise.
Based in Pleasanton, CA, The Cooper Companies is a specialty medical device company operating on a global basis. It operates through two business segments, namely CooperVision and CooperSurgical.
Stocks to Consider
Better-ranked stocks in the broader medical sector include Inogen Inc. (INGN - Free Report) , Avinger, Inc. (AVGR - Free Report) and Fluidigm Corporation . Notably, Inogen sports a Zacks Rank #1 (Strong Buy), while Fluidigm and Avinger carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Inogen has a long-term expected earnings growth rate of 17.05%. Notably, the stock has an impressive one-year return of 77.4%.
Avinger projects sales growth of 30.6% for the current year. Additionally, the company delivered a positive earnings surprise of 27% last quarter.
Fluidigm Corporation has a long-term expected earnings growth rate of 25%. The stock added 6.08%, in the last one year.
5 Trades Could Profit ""Big-League"" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>